Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study - Scorecard - MDSpire
Advertisement
Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study
Clinical Scorecard: Evaluation of Safety and Immune Response of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: Results from a Randomized Placebo-Controlled Phase 1 Trial
At a Glance
Category
Detail
Condition
Clostridioides difficile infection (CDI), a bacterial infection causing diarrhea and severe gut mucosa damage
Key Mechanisms
Vaccine targets toxins A (TcdA) and B (TcdB) of C. difficile using F2 antigen; AS01 adjuvant enhances immune response
Target Population
Healthy adults aged 18–45 and 50–70 years
Care Setting
Preventive vaccination in outpatient or clinical trial settings
Key Highlights
The vaccine candidate containing F2 antigen plus AS01 adjuvant was well tolerated with an acceptable safety profile.
Injection site pain, tiredness, and headache were the most common mild to moderate and transient adverse events, more frequent with adjuvanted vaccine.
Immunogenicity was substantially higher with F2 antigen plus AS01 compared to F2 antigen alone; a third dose boosted response in subjects with low baseline neutralization titers.
Guideline-Based Recommendations
Diagnosis
CDI diagnosis based on clinical presentation and detection of toxins A and B.
Management
Current treatment is antibiotic therapy; adjunctive bezlotoxumab recommended for recurrent CDI except in patients with congestive heart failure.
Active immunization with vaccines targeting toxins A and B is under investigation for prevention.
Monitoring & Follow-up
Monitor for solicited adverse events for 7 days and unsolicited adverse events for 30 days post-vaccination.
Assess immunogenicity via neutralization titers at baseline and after each vaccine dose.
Risks
Adverse events mostly mild to moderate and transient; no serious vaccine-related adverse events observed.
Higher reactogenicity expected with adjuvanted vaccine formulations.
Patient & Prescribing Data
Healthy adults aged 18–70 years without contraindications to vaccination.
Two doses of F2 antigen plus AS01 adjuvant elicit strong neutralizing antibody responses; a third dose enhances immunity in those with low baseline titers.
Clinical Best Practices
Consider adjuvanted vaccine formulations to enhance immunogenicity against C. difficile toxins.
Administer two doses one month apart, with a potential third dose after 15 months for improved response in low responders.
Monitor patients for common mild to moderate adverse events such as injection site pain, fatigue, and headache.
Exclude patients with contraindications and monitor for serious adverse events, although none were related to the vaccine in this study.
by Isabel Leroux-Roels, Azhar Alhatemi, Magalie Caubet, Fien De Boever, Bertrand de Wergifosse, Mohamed El Idrissi, Guilherme S Ferreira, Bart Jacobs, Axel Lambert, Sandra Morel, Charlotte Servais, Juan Pablo Yarzabal
